Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Business

CVS replaces CEO Karen Lynch with David Joyner as shares tank

CVS Health on Friday replaced CEO Karen Lynch with David Joyner, a CVS veteran who retired before returning to the company last year, after investors including activist Glenview Capital pressured the company to improve its stagnant share price.

It also withdrew its 2024 forecast and gave an outlook for third-quarter earnings far below analyst estimates.

CVS shares closed down 5% at $60.34 on Friday.

CVS shares dropped on Friday as it replaced CEO Karen Lynch, who took over in 2021. AP

They are down by nearly half from their 2022 highs, in part due to quarter after quarter of repeated profit forecast cuts related to rising costs in its large health care insurance business and competition for its vast network of retail pharmacies.

Its third business — pharmacy benefit management — has been profitable but a focal point for US government efforts to bring down drug prices.

The Federal Trade Commission sued it and its rivals last month.

“The board believes this is the right time to make a change, and we are confident that David is the right person to lead our company,” CVS chairman Roger Farah said in a statement.

CVS on Friday said it expected adjusted profit of $1.05 to $1.10 per share for the quarter ended Sept. 30 compared to analysts’ estimates of $1.70, according to data compiled by LSEG.

CVS was already growing rapidly beyond its retail pharmacy footprint when it bought health insurer Aetna in 2017, a move it said was needed to try to rein in health care costs and as it faced new health care competition from Amazon and others.

CVS’ board said it believes this is the right time to make a change to new CEO David Joyner. AP
Sources said CVS planned to remain as one company under Joyner. AP

In 2021, former Aetna executive Lynch took over as CEO and the company’s shares soared as it benefited from its role in the COVID-19 pandemic recovery.

Wall Street analysts have said the company failed to find the benefits that could come from integration of different acquired businesses.

“This move was brewing for some time, as CVS has struggled under Lynch’s leadership following the failed Aetna merger,” said Oppenheimer analyst Michael Wiederhorn.

Glenview went public earlier this month with its concerns, and sources said a strategic review that could include a split of the company’s core businesses was on the table.

In a statement to employees, Joyner, who is on the board of directors, said that in order to succeed, the company would need to operate as “one CVS Health.”

Two sources familiar with the situation said CVS planned to remain one company under Joyner.

Glenview said Friday that CVS needed to make changes to both leadership and the board.

“We believe the Company’s culture, governance and leadership should be strengthened by those with both appropriate industry experience as well as fresh perspectives and that the Company would be best served through prompt Board evolution,” it said in a statement.

It said the company’s Medicare insurance division, which accounts for one-third of its business, was “quite fixable.”

Costs for insurers providing Medicare plans — available for people age 65 and above and those with disabilities — have soared in the last year due to sustained high demand from older adults for health care services.

CVS’s third-quarter medical care ratio, the percentage of premiums spent on medical care, is significantly higher at 95.2% than estimates of 90.95%.

The industry generally targets a medical benefit ratio closer to 80%.

Lynch stepped down from her position in agreement with CVS Health’s board, the company said. Joyner, who is president of the company’s pharmacy benefit manager, CVS Caremark, takes over as president and CEO on Friday.

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button